Muwaffaq Salameh, MD
Nephrology · Bay City, MINPI 1851647390
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $137,338 of the $164,451 with a category attached, or 83.5%. AstraZeneca accounts for 60.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $44,090 and has fallen 74.2% since, to $11,371 in 2025. Among nephrology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 459 payments — averaging $358.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$100K
- Bayer$22K
- Otsuka America Pharmaceutical, Inc.$22K
- Akebia Therapeutics Inc$16K
- GSK$1K
- Calliditas Therapeutics US Inc.$533
- plus $3K from 18 others
What the payments were for
- Consulting fees$6,0304%
- Speaking & faculty fees$137,33884%
- Travel & lodging$10,6746%
- Food & beverage$10,3666%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 201 | $99,547 |
| Bayer | 30 | $22,494 |
| Otsuka America Pharmaceutical, Inc. | 64 | $21,686 |
| Akebia Therapeutics Inc | 30 | $16,198 |
| GSK | 2 | $1,306 |
| Calliditas Therapeutics US Inc. | 21 | $533 |
| Amgen(2 entities) | 28 | $513 |
| Travere Therapeutics, Inc. | 16 | $261 |
| Mozarc Medical US LLC | 2 | $234 |
| Fresenius USA Marketing, Inc. | 4 | $209 |
| Baxter Healthcare | 3 | $203 |
| Boehringer Ingelheim | 12 | $203 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $175 |
| Novo Nordisk | 8 | $161 |
| Novartis | 7 | $149 |
| Aurinia Pharma U.S., Inc. | 8 | $135 |
| Vantive US Healthcare LLC | 2 | $101 |
| Mallinckrodt Enterprises LLC | 4 | $78 |
| Mallinckrodt Hospital Products Inc. | 5 | $69 |
| Ardelyx, Inc. | 3 | $67 |
| Vertex | 1 | $53 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Scpharmaceuticals Inc. | 2 | $27 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,451 in reported general payments places this provider in the 95th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 314 | $379,352 |
| TarpeyoBudesonide | 12 | $193,427 |
| JardianceEmpagliflozin | 117 | $168,029 |
| KerendiaFinerenone | 21 | $39,180 |
| XphozahTenapanor Hcl | 12 | $35,455 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $28,792 |
| AuryxiaFerric Citrate | 20 | $14,466 |
| SpsSodium Polystyrene Sulfon/Sorb | 29 | $10,885 |
| Metolazone | 210 | $9,983 |
| Bumetanide | 161 | $9,085 |
| Clonidine | 48 | $6,930 |
| Hydralazine Hcl | 322 | $6,090 |
| Gentamicin Sulfate | 41 | $4,830 |
| Potassium Chloride | 171 | $4,820 |
| Sevelamer Carbonate | 31 | $4,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $99,547 | $408,144345 claims |
| Calliditas Therapeutics US Inc.Tarpeyo | $533 | $193,42712 claims |
| Boehringer IngelheimJardiance | $203 | $168,029117 claims |
| BayerKerendia | $22,494 | $39,18021 claims |
| Akebia Therapeutics IncAuryxia | $16,198 | $14,46620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 325 nephrology providers in Michigan.
Other nephrology in Bay City
- Alexander YevzlinAnn Arbor$1.1M
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
- Richard CrossSaint Clair Shores$96K
- Kausik UmanathDetroit$85K
- Joel TopfRoseville$79K
- Matthias KretzlerAnn Arbor$70K
- Claudia ZacharekSaginaw$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.